Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy.
BACKGROUND
Iron deficiency constitutes the major cause of erythropoietin hyporesponse in uremic patients receiving erythropoietin therapy; therefore, iron supplementation is necessary for these patients. Recent data suggested that intravenous iron supply is a preferable route for iron supplementation. However, it remains unclear whether a single large dose or multiple small doses are a better way of administering an intravenous iron supply.


METHODS
To determine the effect of different dosing schedules of intravenous iron therapy on the hematocrit level, we randomly assigned 18 patients to 3 groups. The first group of patients (n = 6) received a single dose of 800 mg intravenous fesin (ferric saccharate). The second group of patients (n = 6) received 400 mg intravenous fesin once weekly for 2 successive weeks. The third group of patients (n = 6) received 120 mg of intravenous fesin for 7 successive hemodialysis sessions. EPO was given at a fixed dose for all individuals in the study period.


RESULTS
The results showed that all 3 groups of patients had a progressive increase in hematocrit (Hct) level following intravenous iron therapy. Serum ferritin levels increased rapidly following iron therapy and then declined gradually in all 3 groups. But no statistical significance could be found among the 3 groups because of the small patient number. Also, no differences were observed in Hct or serum ferritin levels among these 3 groups of patients at all stages.


CONCLUSIONS
In this study, we found that a large single dose as well as small multiple doses of parenteral iron therapy had similar effects in correcting the iron deficiency in hemodialysis patients treated with erythropoietin. To save manpower and costs, we recommend the large single dosing schedule.
Kao
H H
HH
Division of Nephrology, Department of Internal Medicine, Chang Gung Memorial Hospital, 222 Mai-Chin Road, Keelung, Taiwan, R.O.C.
Chen
K S
KS
Tsai
C J
CJ
Lee
C C
CC
Chang
H Y
HY
D000740:Anemia / Q000209:etiology / Q000628:therapy; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage*; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood; D005937:Glucaric Acid; D006400:Hematocrit; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D000090463:Iron Deficiencies; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000628:therapy
D005290:Ferric Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid